GLP-1 prescriptions surge in US children
Analysis based on 8 articles · First reported Sep 04, 2026 · Last updated Sep 08, 2026
The study underscores the rapid expansion of GLP-1 drug use into pediatric populations, potentially broadening the market for Novo Nordisk and Eli Lilly and Company. Increased demand could boost revenues for these manufacturers, though concerns about access and long-term safety may influence regulatory and prescribing practices.
A study led by NYU Langone Health, published in the journal Pediatrics on September 4, 2026, found that prescriptions for GLP-1 weight-loss drugs (Saxenda, Wegovy, Zepbound) among US children aged 8-11 with obesity increased 310-fold from 2019 to June 2026. The proportion rose from 0.03% to 9.3%, with over 20,000 children prescribed. Most had severe obesity and related conditions. The study highlighted an access gap, with children from upper-income communities 55% more likely to receive prescriptions. Researchers called for ensuring equitable access and long-term monitoring. Clinical trials are underway for children as young as 6.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard